当前位置: X-MOL 学术Bioconjugate Chem. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Biotinylated Streptavidin Surface Coating Improves the Efficacy of a PLGA Microparticle-Based Cancer Vaccine.
Bioconjugate Chemistry ( IF 4.0 ) Pub Date : 2020-08-12 , DOI: 10.1021/acs.bioconjchem.0c00347
Brett P Gross 1 , Khanidtha Chitphet 2 , Amaraporn Wongrakpanich 2, 3 , Emad I Wafa 2 , Lyse A Norian 4 , Aliasger K Salem 2
Affiliation  

Triple-negative breast cancer (TNBC) is an immune-enriched subset of breast cancer that has recently demonstrated clinical responsiveness to combinatorial immunotherapy. However, the lack of targeted interventions against hormone receptors or HER2 continues to limit treatment options for these patients. To begin expanding available interventions for patients with metastatic TNBC, we previously reported a therapeutic vaccine regimen that significantly reduced spontaneous lung metastases in a preclinical TNBC model. This heterologous vaccine approach “primed” mice with tumor lysate antigens encapsulated within poly(lactic-co-glycolic) acid microparticles (PLGA MPs), and then “boosted” mice with tumor lysates plus adjuvant. The use of the PLGA MP prime as monotherapy demonstrated no efficacy, suggesting that improving this component of our therapy would achieve greater vaccine efficacy. Here, we functionally improved the PLGA MP prime by coating microparticles with biotinylated streptavidin-conjugated using 1-ethyl-3-(3-dimethylaminoproplyl) carbodiimide/N-hydroxysuccinimide (EDC/Sulfo-NHS) linkers. This modification enhanced the immunostimulatory potential of our PLGA MPs, as evidenced by increased phagocytosis, maturation, and stimulatory ligand expression by antigen-presenting cells (APCs). Therapeutic prime/boost vaccination of TNBC-bearing mice with surfaced-coated PLGA MPs significantly reduced spontaneous lung metastases by an average of 56% relative to mice primed with unmodified PLGA MPs, and a significant 88% average reduction in spontaneous lung metastases relative to untreated control mice. These findings illustrate that relatively common biotin–streptavidin conjugation formulations can positively affect microparticle-based vaccine immunogenicity resulting in enhanced therapeutic efficacy against established preclinical mammary tumors.

中文翻译:

生物素化的链霉亲和素表面涂层可改善基于PLGA微粒的癌症疫苗的功效。

三阴性乳腺癌(TNBC)是乳腺癌的一种免疫富集子集,最近已显示出对组合免疫疗法的临床反应能力。但是,缺乏针对激素受体或HER2的靶向干预措施继续限制了这些患者的治疗选择。为了开始扩大对转移性TNBC患者的可用干预措施,我们先前报道了一种治疗性疫苗方案,可在临床前TNBC模型中显着减少自发性肺转移。这种异源疫苗的方法“打底”小鼠肿瘤裂解物抗原包封内聚(乳酸--乙醇酸)微粒(PLGA MPs),然后用肿瘤溶解产物和佐剂“增强”小鼠。PLGA MP素作为单一疗法的使用并未显示出任何功效,这表明改进我们疗法的这一成分将获得更大的疫苗功效。在这里,我们在功能上改进了PLGA MP素,方法是使用1-乙基-3-(3-二甲基氨基丙基)碳二亚胺/ N包覆生物素化的抗生物素蛋白链菌素包被微粒-羟基琥珀酰亚胺(EDC / Sulfo-NHS)接头。这种修饰增强了我们PLGA MP的免疫刺激潜能,这通过抗原呈递细胞(APC)的吞噬作用,成熟和刺激性配体表达增加而得到证明。表面涂有PLGA MP的TNBC小鼠的治疗性初免/加强免疫接种相对于未经修饰的PLGA MP致敏的小鼠,平均可显着减少自发性肺转移,相对于未经治疗的小鼠,其自发性肺转移平均可降低88%对照小鼠。这些发现表明,相对常见的生物素-链霉亲和素结合制剂可以对基于微粒的疫苗免疫原性产生积极影响,从而提高针对已建立的临床前乳腺肿瘤的治疗效果。
更新日期:2020-09-16
down
wechat
bug